Intact Vascular to Sponsor Post-Angioplasty Dissection Symposium and Present an Update on the TOBA II Pivotal Study Results at the 2018 VEITHsymposium

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

November 12, 2019:

Intact Vascular, Inc., a private medical device company committed to developing solutions for minimally invasive peripheral vascular procedures, today announced the schedule of key presentations to be featured during a lunch symposium co-sponsored with Philips at the 45th annual VEITHsymposium conference in New York City on Thursday, November 15th. Following the symposium, an update on the company’s TOBA II pivotal trial will be presented. (The Tack Endovascular System will be on display at Intact Vascular’s exhibitor booth, #215.)

Intact Vascular’s Tack Endovascular System®, a first-of-its-kind dissection repair device, is designed to preserve vessel integrity and enhance blood flow following balloon angioplasty. Patients with peripheral arterial disease (PAD) who are treated with balloon angioplasty often suffer from dissections or tears that are frequently overlooked, undiagnosed and untreated. These dissections can compromise clinical outcomes, resulting in acute thrombosis and arterial occlusions, leading to lower long-term patency rates and repeat procedures. Research has shown that intravascular ultrasound (IVUS) helps to visualize these dissections, confirming their presence and severity, often not visualized on traditional angiography1.

“The clinical impact of post-angioplasty dissections, although often under-diagnosed and under-estimated, is in fact substantial and can lead to high rates of restenosis and re-intervention,” said Bruce Shook, President and CEO of Intact Vascular. “Our symposium highlights the importance of IVUS to assist in the diagnosis of dissections and the clinical significance of the Tack Endovascular System to minimize further complications and improve the frequently painful, debilitating symptoms for these patients.”

The co-sponsored lunch symposium, “Leave no dissection behind; improve what you see, repair with precision”, will be held from 12:30-1:30PM in the Gramercy Suite West, New York Hilton Midtown and will include the following presentations:

  • Dissections matter and they matter even more in the DCB era: Evidence above and below the knee – presented by Ehrin Armstrong, MD
  • iDissection: using IVUS to see what we are missing: iDissection classification system using intravascular imaging – presented by Nicolas Shammas, MD
  • Tack optimized angioplasty: results from TOBA II: Twelve-month pivotal trial results – presented by William Gray, MD
  • Precision dissection repair: European experience with the Tack Endovascular System® – presented by Michael Lichtenberg, MD

Following the lunch symposium, Dr. Marianne Brodmann from the Medical University of Graz in Austria, will present Update on the Value of Tack Assisted Balloon Angioplasty: Results of the TOBA II Study: Do the Tacks Improve PTA Patency In The Femoropopliteal Segment? from 2:40-2:45PM in the Grand Ballroom West, 3rd Floor.





Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.